Categories

Meta

Recent Posts

Archive for June, 2010

Grifols to obtain Pharmalink’s Xepol summary respecting post-polio syndrome

Posted in Child Health on June 30th, 2010

– Unanimity Marks Milestone in Pharmalink’s Corporate Happening

Pharmalink AB, today announced that it has closed its settlement with Grifols SA looking for the possessions of Pharmalink’s Xepol(R) organize fitting for the treatment of post-polio syndrome (PPS). The parties had in the old days announced reaching an covenant whereby Grifols would into all know-how and extensive mastermind attribute rights mutual to the make use of of Read the rest of this entry »

Calistoga Pharmaceuticals closes $40 million Series C financing

Posted in Drug Trial on June 30th, 2010

Calistoga Pharmaceuticals, Inc., the gaffer in the incident of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors an eye to the treatment of cancer and revolutionary diseases, today announced it has closed a $40 million Series C financing. The financing was led in particular Quogue Splendid, LLC along with existing investors Alta Partners, Amgen Ventures, Frazier Healthcare and Three Designing Partners and late-model investor Latterell Read the rest of this entry »

ResponseDX: Lung genetic check up on panel launched to uncover EML4-ALK gene variants in lung cancer patients

Posted in Medical Condition on June 30th, 2010

Comeback Genetics Inc. (Nasdaq: RGDX), a companions focused on the enlargement and in stock of molecular diagnostic tests for the sake cancer, today announced that it has expanded its ResponseDX: Lung™ genetic evaluation panel to dig up the carriage of EML4-ALK gene variants in lung cancer patients. EML4-ALK fusion genes are baksheesh in close by four percent of tumors from patients with non-small stall lung cancer (NSCLC). These rearranged Read the rest of this entry »

Roche, IBM broadcast concurrence to upon nanopore-based sequencer in regard to decoding DNA

Posted in Medical Research on June 30th, 2010

Roche (SWX:RO)(SWX:ROG)(Pink Sheets: RHHBY) and IBM (NYSE: IBM) announced today an harmony to upon a nanopore-based sequencer that resolution as the crow flies be familiar with and decode lenient DNA on the double and efficiently. Focused on advancing IBM’s recently published "DNA Transistor" technology, the collaboration when one pleases perform upper hand of IBM’s influence in microelectronics, communication technology and computational Read the rest of this entry »

ICON Medial Laboratories partners with FMD to unwrapped green laboratory masterliness in China

Posted in Medical Research on June 30th, 2010

ICON Inner Laboratories – a dividing of ICON plc, (NASDAQ:ICLR) (ISIN:IE0005711209), a epidemic provider of outsourced expansion services to the pharmaceutical, biotechnology and medical ploy industries – today announced the pit of a unique laboratory john in Tianjin, China, in partnership with Well-spring Medical Increase Ltd (FMD). It is the third ICON laboratory in the Asia-Pacific precinct.

“Our bond with Fountain-head Medical Read the rest of this entry »

SuperGen encouraged nearby Eisai’s almost as good as to rank Dacogen sNDA suited for unfamiliar symptom

Posted in Drug Trial on June 30th, 2010

SuperGen, Inc. (Nasdaq: SUPG), a pharmaceutical companionship dedicated to the unearthing and growth of unfamiliar cancer therapies, announced that Eisai Inc. today released tidings in any case a randomized Taper off III clinical plague of Dacogen® (decitabine) someone is concerned Injection in senescent patients with clever myeloid leukemia (AML). The comparator in this stab was low-dose cytarabine, a chemotherapy means, or reassuring be keen Read the rest of this entry »

BioSante reports beneficial results from Facet II bone up on of Pill-Plus "triple hormone" pronounced contraceptive

Posted in Drug Trial on June 30th, 2010

BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) announced today total results in a Stage II boning up of the Pill-Plus "triple hormone" articulated contraceptive (OC). Results showed an grow in the frequency of propagative pursuit (p< 0.05) and reduced frequency of the old heave-ho of origination of physical occupation by means of sharer (p< 0.05).

“We are glad with the results to engagement in the clinical favour being carried-out Read the rest of this entry »

Cubist commences enrollment in Taper off 2 muse about of CXA-201 instead of compound intra-abdominal infections

Posted in Disease, Infection on June 30th, 2010

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST), a best alert attention therapeutics companions, today announced the enrollment of the first off tireless in a Moment 2 scrutiny with CXA-201. This multicenter, double-blind, randomized, con wish rival the security and efficacy of intravenous CXA-201 with an powerful comparator in patients with elaborate intra-abdominal Infections (cIAI). This ecumenical scrutiny is expected to enroll 120 patients. Read the rest of this entry »

Eisai reports prefatory results from Dacogen destined for Injection Period III observe in AML

Posted in Drug Trial on June 30th, 2010

Eisai Inc. announced today prolegomenon results from a randomized Taper off III clinical judicial proceeding of Dacogen® (decitabine) looking for Injection versus either a low-dose chemotherapy spokesperson or helpful keeping in aged patients with keen myeloid leukemia (AML), a life-threatening cancer of the blood that habitually occurs in older adults.

The elementary endpoint of this memorize was complete survival. Although Dacogen Read the rest of this entry »

CDC issues callow guidelines on detection of Mycobacterium tuberculosis infections

Posted in Disease, Infection on June 30th, 2010

Today the Amalgamated States (U.S.) Centers in regard to Condition Rule and Inhibition (CDC) issued fashionable and effective guidelines on the detection of Mycobacterium tuberculosis infections, the causative intermediary of tuberculosis (TB). In these critical guidelines, CDC advises that Interferon Gamma Make available Assay (IGRA) blood tests are in these times preferred outstanding the 100+-year-old tuberculin crust assay (TST) appropriate Read the rest of this entry »